|Prof. Andrew L. Hopkins DPHIL, FMEDSCI, FRSE FRSC||Founder, CEO & Executive Director||628,19k||N/A||1973|
|Mr. Ben R. Taylor||CFO, Chief Strategy Officer & Executive Director||440,34k||N/A||1977|
|Dr. David Hallett Ph.D.||Chief Scientific Officer||N/A||N/A||1971|
|Dr. Garry Pairaudeau Ph.D.||Advisor||N/A||N/A||1966|
|Dr. Michael Krams M.D.||Chief Quantitative Medicine Officer||N/A||N/A||1961|
|Ms. Eileen Jennings-Brown||Chief Information Officer||N/A||N/A||N/A|
|Ms. Sara Sherman||Vice President of Investor Relations||N/A||N/A||N/A|
|Mr. Dan Ireland||Vice President of Legal & Company Secretary||N/A||N/A||N/A|
|Ms. Caroline Rowland||Chief People Officer||N/A||N/A||N/A|
|Mr. Richard Law||Chief Business Officer||N/A||N/A||N/A|
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Exscientia plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.